Blueprint Medicines' Series A Round

Blueprint Medicines raised a round of funding on April 11, 2011. Investors include Third Rock Ventures.

Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancers. Led by a management team and advisors with world…

Articles about Blueprint Medicines' Series A Round: